EUCTR2013-003884-71-DK进行中（未招募）1 期
A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) - TOPAZ
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,248
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patient has completed at least 48 months of the Extension Study CAMMS03409
- •- Signed written informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1248
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patient participating in another investigational interventional study
研究者
相似试验
进行中（未招募）
1 期
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409Relapsing-remitting multiple sclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-003884-71-CZGenzyme Corporation1,248
进行中（未招募）
1 期
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409EUCTR2013-003884-71-ITGenzyme Corporation799
进行中（未招募）
1 期
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409Relapsing-remitting multiple sclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-003884-71-NLGenzyme Corporation1,248
进行中（未招募）
1 期
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409Relapsing-remitting multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-003884-71-ESGenzyme Corporation1,062
进行中（未招募）
1 期
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409EUCTR2013-003884-71-HRGenzyme Corporation1,062